{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-088728","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2026-07-30T20:30:36+00:00","discovered_at":"2026-07-30T20:32:00.333173+00:00","generated_at":"2026-07-30T20:32:17.860914+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BrainStorm appoints former FDA official Peter Pitts as Executive Chairman; Frenkel and Dagher depart","bullets":["Peter Pitts, former FDA Associate Commissioner, appointed Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026.","Jacob Frenkel resigned as Chairman and director; transitions to Senior Advisor with 100,000 RSUs vesting over 6 months.","Ibrahim Dagher resigned as EVP and Chief Medical Officer on July 26, 2026; will consult for one year with equity vesting.","Pitts will lead NurOwn Phase 3b trial under first-ever FDA Special Protocol Assessment for an ALS therapeutic.","Pitts receives option for 900,000 shares vesting over 4 years; no salary or cash bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-088728","json":"https://secwatch.observer/filing/0001104659-26-088728.json","markdown":"https://secwatch.observer/filing/0001104659-26-088728.md","text":"https://secwatch.observer/filing/0001104659-26-088728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/0001104659-26-088728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/tm2621592d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:32:17.860914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}